What is SWOBY stock price today?

SWOBY (Swedish Orphan Biovitrum AB (publ)) stock is trading at $19.63 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is SWOBY stock going up or down today?

SWOBY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy SWOBY stock now?

The decision to buy SWOBY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is SWOBY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for SWOBY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is SWOBY stock overvalued or undervalued?

SWOBY currently trades at a P/E ratio of 280.39, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if SWOBY is fairly priced.

What is SWOBY's P/E ratio?

SWOBY has a price-to-earnings (P/E) ratio of 280.39, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is SWOBY's market cap?

SWOBY (Swedish Orphan Biovitrum AB (publ)) has a market capitalization of $14.20 billion, making it a mid-cap stock.

What is SWOBY's price to book ratio?

SWOBY trades at a price-to-book (P/B) ratio of 3.41, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does SWOBY pay dividends?

SWOBY does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is SWOBY's dividend yield?

SWOBY does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is SWOBY stock a good long-term investment?

SWOBY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is SWOBY's revenue growth rate?

SWOBY has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, SWOBY is profitable with a profit margin of 0.0%. This indicates the company generates 0.0 cents of profit for every dollar of revenue.

What are the risks of investing in SWOBY?

Key risks for SWOBY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does SWOBY compare to its competitors?

Compare SWOBY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize SWOBY's performance and positioning.

What is SWOBY's stock price target for 2026?

Our AI model provides price targets for SWOBY based on fundamental analysis: Bull case $25.52 (+30%), Base case $22.57 (+15%), Bear case $17.66 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about SWOBY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for SWOBY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is SWOBY's next earnings report?

SWOBY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

SWOBY - Swedish Orphan Biovitrum AB (publ)

NYSE * Healthcare * Drug Manufacturers - Specialty & Generic

$19.63

+$0.00 (+0.00%)

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.

SWOBY Key Statistics

Market Cap

$14.20B

P/E Ratio

280.39

P/B Ratio

3.41

EPS

$0.07

Revenue Growth

+0.1%

Profit Margin

0.0%

Employees

1,862

How SWOBY Compares to Peers

SWOBY trades at a premium valuation vs peers (highest P/E)

SWOBY is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
SWOBY(This stock)	$14.20B	280.4	0%	0.0%	-
LLYEli Lilly	$809.09B	39.3	0%	0.3%	vs LLY
JNJJohnson &	$575.17B	21.8	0%	0.2%	vs JNJ
PFEPfizer Inc	$154.67B	20.0	-0%	0.1%	vs PFE
MRKMerck &	$291.50B	16.2	0%	0.3%	vs MRK
ABBVAbbvie Inc	$368.65B	87.6	0%	0.1%	vs ABBV

Swedish Orphan Biovitrum AB (publ) Company Information

Headquarters: Norra Stationsgatan 93A, Stockholm, Sweden, undefined
Website: www.sobi.com
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

About Swedish Orphan Biovitrum AB (publ)

SWOBY Key Statistics

How SWOBY Compares to Peers

Swedish Orphan Biovitrum AB (publ) Company Information

Upcoming Events for SWOBY